Nimenrix®

The full indication for Nimenrix® is active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis group A, C, W135 and Y.1

Since September 2019, as part of the HSE Schools Immunisation Programme, students in their first year of secondary school are offered a meningococcal ACWY booster (MenACWY) vaccination, Nimenrix®.2

MenACWY immunisation is recommended for certain people at increased risk due to a medical condition or treatment.3,4

Nimenrix® is the only ACWY meningococcal vaccine with persistence of bactericidal antibodies evaluated for up to 10 years.1

 

 

References

  1. Nimenrix® Summary of Product Characteristics.
  2. MenACWY Schools Immunisation Programme. Available at: https://www.hse.ie/eng/health/immunisation/pubinfo/schoolprog/menacwy/ Last accessed: July 2022.
  3. National Immunisation Advisory Committee. Immunisation Guidelines. Chapter 13, Meningococcal Infection. Available at: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf Last accessed: July 2022.
  4. National Immunisation Advisory Committee. Immunisation Guidelines. Chapter 3, Immunisation of Immunocompromised Persons. Available at: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter3.pdf Last accessed: July 2022.

 

Nimenrix® can be ordered directly from us:1800 249 349

 

View Summary of Product Characteristics



Legal Category: S1A

PP-NIM-IRL-0020 Preparation Date July 2022